carvykti
janssen-cilag international nv - ciltacabtagene autoleucel - multiple myeloma - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.
quetiapin sandoz 100 mg filmomh. tabl.
sandoz sa-nv - quetiapinefumaraat 115,13 mg - eq. quetiapine 100 mg - filmomhulde tablet - quetiapine
quetiapin sandoz 200 mg filmomh. tabl.
sandoz sa-nv - quetiapinefumaraat 230,26 mg - eq. quetiapine 200 mg - filmomhulde tablet - quetiapine
quetiapin sandoz 25 mg filmomh. tabl.
sandoz sa-nv - quetiapinefumaraat 28,78 mg - eq. quetiapine 25 mg - filmomhulde tablet - quetiapine
quetiapin sandoz 300 mg filmomh. tabl.
sandoz sa-nv - quetiapinefumaraat 345,39 mg - eq. quetiapine 300 mg - filmomhulde tablet - quetiapine
quetiapine ab 100 mg filmomh. tabl.
aurobindo sa-nv - quetiapinefumaraat 115,122 mg - eq. quetiapine 100 mg - filmomhulde tablet - quetiapine
quetiapine ab 100 mg filmomh. tabl.
aurobindo sa-nv - quetiapinefumaraat 115,122 mg - eq. quetiapine 100 mg - filmomhulde tablet - quetiapine
quetiapine ab 200 mg filmomh. tabl.
aurobindo sa-nv - quetiapinefumaraat 230,244 mg - eq. quetiapine 200 mg - filmomhulde tablet - quetiapine
quetiapine ab 200 mg filmomh. tabl.
aurobindo sa-nv - quetiapinefumaraat 230,244 mg - eq. quetiapine 200 mg - filmomhulde tablet - quetiapine
quetiapine ab 25 mg filmomh. tabl.
aurobindo sa-nv - quetiapinefumaraat 28,78 mg - eq. quetiapine 25 mg - filmomhulde tablet - quetiapine